Method and compositions for immunization with the
View Patent ↗A method of inhibiting, moderating or diagnosing Pseudomonas aeruginosa infection is disclosed. In one embodiment, this method comprises inoculating a patient with an effective amount of PcrV antigen.
1. An isolated monoclonal antibody that specifically binds to Pseudomonas aeruginosa PcrV antigen, wherein the antibody comprises a heavy chain (SEQ. ID NO: 2) and a light chain (SEQ. ID NO: 4) wherein the antibody or a fragment thereof specifically binds to an epitope that includes amino acid residues 144 through 257 of SEQ ID NO: 7 in Pseudomonas aeruginosa PcrV antigen.
2. The antibody of claim 1 , wherein the antibody or a fragment thereof is humanized.
3. The antibody of claim 1 , wherein the antibody or a fragment thereof is human.
4. A pharmaceutical composition comprising an isolated monoclonal antibody or fragment thereof that specifically binds to Pseudomonas aeruginosa PcrV antigen, wherein the antibody comprises a heavy chain (SEQ. ID NO: 2) and a light chain (SEQ. ID NO: 4), and a pharmaceutically acceptable carrier.
5. The pharmaceutical composition of claim 4 in an effective amount for treating Pseudomonas aeruginosa infection in a patient.
6. A method for treating Pseudomonas aeruginosa infection in a patient comprising administering to the patient an effective amount of the composition of claim 4 .
7. A method for reducing pathogenicity of Pseudomonas aeruginosa infection in a patient comprising administering to the patient an effective amount of the composition of claim 4 .
8. The composition of claim 4 additionally comprising an antibiotic.
9. The method of claim 6 additionally comprising the step of administering antibiotic therapy to the patient.
10. The composition of claim 4 , wherein the fragment is selected from an Fab or Fab′ fragment.
11. The method of claim 6 , wherein the patient is a cystic fibrosis patient.
12. An isolated monoclonal antibody that specifically binds to amino acid residues 144 through 257 of SEQ ID NO: 7 in Pseudomonas aeruginosa PcrV.
13. The antibody of claim 12 , wherein the antibody comprises a heavy chain (SEQ. ID NO: 2) and a light chain (SEQ. ID NO: 4).
14. A pharmaceutical composition comprising an isolated monoclonal antibody or fragment thereof that specifically binds to amino acid residues 144 through 257 of SEQ ID NO: 7 in Pseudomonas aeruginosa PcrV, and a pharmaceutically acceptable carrier.
15. The pharmaceutical composition of claim 14 in an effective amount for treating Pseudomonas aeruginosa infection in a patient.
16. A method for treating Pseudomonas aeruginosa infection in a patient comprising administering to the patient an effective amount of the composition of claim 14 .
17. The composition of claim 14 additionally comprising an antibiotic.
18. The method of claim 16 additionally comprising the step of administering antibiotic therapy to the patient.
19. The composition of claim 14 , wherein the fragment is selected from an Fab or Fab′ fragment.
20. The method of claim 16 , wherein the patient is a cystic fibrosis patient.
21. The antibody of claim 12 wherein the antibody or fragment thereof is humanized.
22. The antibody of claim 12 wherein the antibody or fragment thereof is human.